Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5C2 | P49902 | 2/20 | 0.69 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618808 | 0.90 | NT5C2 (0.67) | NT5C2NT5EBRD4CSF1RPDPK1 | |
| SCHEMBL23123 | 0.90 | BRD4 (0.64) | NT5C2NT5EBRD4CREBBPCSF1R | |
| SCHEMBL8381773 | 0.88 | BRD4 (0.63) | NT5C2NT5EBRD4CREBBPCSF1R | |
| SCHEMBL6463473 | 0.86 | BRD4 (0.60) | NT5C2NT5EBRD4CREBBPCSF1R | |
| SCHEMBL2623134 | 0.85 | KCNQ3 (0.51) | NT5C2NT5EBRD4CREBBPGRM5 | |
| SCHEMBL16619414 | 0.82 | NPC1 (0.48) | NT5C2NT5EBRD4SIRT2 | |
| SCHEMBL18066325 | 0.80 | CHRNB2 (0.50) | NT5C2NT5EBRD4 | |
| SCHEMBL2623133 | 0.76 | BRD4 (0.49) | NT5C2BRD4CREBBP | |
| SCHEMBL18486378 | 0.76 | TOP2A (0.49) | NT5C2NT5EEGFR | |
| SCHEMBL16619169 | 0.75 | MAPT (0.50) | BRD4HDAC8AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | claimed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | claimed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | claimed |
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | disclosed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | NTPCR, NT5E, PNP | NT5C2 5/4885NT5E 2/4885BRD4 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.